Article information
Full text is only aviable in PDF
Bibliografía
[1.]
H. Spencer.
Carcinoma of the lung. En: Pathology of the lung.
4.a, Pergamon Press, (1985), pp. 773-859
[2.]
Cancer Research Campaign.
Lung cancer and smoking.
Fact Sheeet II. Cancer in the European Community. Fact Sheet V, Cancer Research Campaign, (1992),
[3.]
D.M. Parkin, A.J. Sasco.
Worldwide variation in occurrence and proporcion atributable to tobacco use.
Lung Cancer, 9 (1993), pp. 1-16
[4.]
L. Fernández Fau, Y.W. Pun, M.J. Espinosa de los Monteros, J.A. Prieto, R. Moreno Balsalobre, A. Acevedo Barbera.
Cáncer de pulmón no células pequeñas.
Manual de neumología y cirugía torácica, pp. 1.511-1.536
[5.]
P.A. Willcox, J.A. O’Brien, R.P. Abratt.
Lung cancer at Groote Schuur Hospital: a local perspective.
S Afr Med J, 78 (1990), pp. 6.176-6.720
[6.]
American Thoracic Society.
Future directions for research on diseases of the lung.
Am J Respir Crit Care Med, 158 (1998), pp. 320-334
[7.]
J.A. Nakhosteen, B. Khanavkar, A. Muti, W. Marek.
Früherkennung des Bronchialkarzinoms durch Autofluoreszenc (LIFE)-Bronchoskopie und automatisierte Sputum Zytometrie: Grund zur Hoffnung.
Atemweg-Lungenkrank, 23 (1997), pp. 211-217
[8.]
J. Castella, C. Puzo.
Neoplasias broncopulmonares.
Broncología, Salvat S.A, (1982), pp. 131-155
[9.]
R.S. Fontana, D.R. Sanderson, W.E. Miller, L.B. Woolner, W.F. Taylor, M.A. Uhlenhopp.
The Mayo Lung Project. Preliminary report of “early cancer detection” phase.
Cancer, 30 (1972), pp. 1.373-1.382
[10.]
W. Weiss, H. Seidman, K.R. Boucot.
The Philadelphia Pulmonary Neoplasm Research Project: thwarting factors in periodic screening for lung cancer.
Am Rev Respir Dis, 111 (1975), pp. 289-294
[11.]
J.J. Bechtell, W.R. Kelley, T.L. Petty, D.S. Patz, G. Saccomanno.
Outcome of 51 patients with roentgenographically occult lung cancer detected by sputum cytologic testing: a community hospital program.
Arch Intern Med, 154 (1994), pp. 975-980
[12.]
A. Kubik, D.M. Parkin, M. Klat, J. Erban, J. Polak, M. Adamec.
Lack of benefit from semi-manual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia.
Int J Cancer, 45 (1990), pp. 26-33
[13.]
R. Fontana, D.R. Sanderson, L.B. Woolner, W.F. Taylor, W.E. Miller, J.R. Muhm.
Lung cancer screening: the Mayo program.
J Occup Med, 28 (1986), pp. 746-750
[14.]
P.C. Prorok, B.F. Hanley, B.N. Bundy.
Concepts and problems in the evaluation of screening program.
J Chronic Dis, 34 (1981), pp. 159-171
[15.]
R.S. Fontana, D.R. Sanderson, W.F. Taylor, L.B. Woolner, W.E. Miller, J.R. Muhm, et al.
Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study.
Am Rev Respir Dis, 130 (1984), pp. 561-565
[16.]
J.M. Siegfried.
Biology and chemoprevention of lung cáncer.
Chest, 113 (1998), pp. 40-45
[17.]
A. Hirvonen.
Genetic factors in individual responses to environmental exposures.
J Occup Environ Med, 37 (1995), pp. 37-43
[18.]
H. Raunio, K. Husgafvel-Pursianen, S. Antilla, E. Hietanen, A. Hirvonen, O. Pelkonen.
Diagnosis of polymorphisms in carcinogenactivating and inactivating enzymes and cancer susceptibility a review.
Gene, 159 (1995), pp. 113-121
[19.]
S.M. Aguayo.
Determinants of susceptibility to cigarette smoke: potential roles for neuroendocrine cells and neuropeptides in airway inflammation, airway wall retnodelling, and chronic airflow obstruction.
Am J Respir Crit Care Med, 149 (1994), pp. 1.692-1.698
[20.]
J.R. Gosney, M. Sissons, R. Allibone, A.F. Blakey.
Pulmonary endocrine cells in bronchitis and emphysema.
J Pathol, 147 (1989), pp. 127-133
[21.]
S.M. Aguayo, M.A. Kane, T.E. King, M.I. Schwartz, L. Grauer, Y.E. Miller.
Increased levels of bombesin-like peptides in the lower respiratory trawct of asymptomatic cigarette sinokers.
J Clin Invest, 84 (1989), pp. 1.105-1.113
[22.]
S.M. Aguayo, Y.E. Miller, T.E. King.
Idiopathic hyperplasia of pulmonary neuroendocrine cells.
N Engl J Med, 328 (1993), pp. 581-582
[23.]
S. Kanjilal, S.S. Strom, G.L. Clayman, R.S. Webwer, A.K. El-Naggar, V. Kapur, et al.
P53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization.
Cáncer Res, 55 (1995), pp. 3.604-3.609
[24.]
G. Sozzi, M. Miozzo, U. Pastorino, S. Pilotti, R. Donghi, M. Giarola, et al.
Genetic evidence for an independent origin of múltiple preneoplasic and neoplastic lung lesions.
Cáncer Res, 55 (1995), pp. 135-140
[25.]
M. Roland, R.M. Rudd.
Somatic mutations in the development of lump cancer.
Thorax, 53 (1998), pp. 979-983
[26.]
T. Strachan, A.P. Read.
Somatic mutations and cancer.
Human molecular genetics, pp. 457-477
[27.]
J.R. Hernández Hernández.
Genética y cáncer de pulmón.
pp. 71-96
[28.]
J.D. Minna.
The molecular biology of lung cancer pathogenesis.
Chest, 103 (1993), pp. 449-456
[29.]
T.G. Krontiris.
Molecular medicine.
Oncogenes. N Engl J Med, 333 (1995), pp. 303-306
[30.]
J.L. Mulshine, A.M. Treston, P.H. Brown, M.J. Birrer, G.L. Shaw.
Initiators and promoters of lung cancer.
Chest, 103 (1993), pp. 4-11
[31.]
F. Molina, M. Monzo, R. Rosell.
Oncogenes en cáncer de pulmón.
Rev Cancer, 8 (1994), pp. 172-177
[32.]
D.P. Carbone.
Oncogenes and tumor suppressor genes.
Hosp Prac, 6 (1993), pp. 145-161
[33.]
M. Benito.
Genes supresores.
Rev Cancer, 9 (1995), pp. 110-114
[34.]
Rodenhuis, R.J.C. Slebos.
Clinical significance of ras oncogenes activation in human lung cancer.
Cancer Res, 52 (1992), pp. 2.665-2.669
[35.]
P.T. Cagle.
Molecular pathology of lung cancer and its clinical relevance.
Monogr Pathol, 36 (1993), pp. 134-144
[36.]
B.E. Johnson.
Biologic and molecular prognostic factors. Impact on treatment of patients with non small cell lung cancer.
Chest, 107 (1995), pp. 287-290
[37.]
M.L.M. Anderson, D.A. Spandidos.
Oncogenes and onco-suppressor genes in lung cancer.
Respir Med, 87 (1993), pp. 413-420
[38.]
D. Shi, G. He, S. Cao, W. Pan, H.Z. Zhang, D. Yu, M.C. Hung.
Overexpression of the c-erbB2/neu-encoded pl85 protein in primary lung cáncer.
Mol Carcinogen, 5 (1992), pp. 213-218
[39.]
R. Salgia, A.T. Skarin.
Molecular abnormalities in lung cancer.
J Clin Oncol, 16 (1998), pp. 1.207-1.217
[40.]
F. Pezzella, H. Turley, I. Kuzu, M.F. Tungekar, M.S. Dunhill, B. Pierce, et al.
Bcl-2 protein in non-small-cell lung carcinoma.
N Engl J Med, 329 (1993), pp. 690-694
[41.]
C. Waker, L. Robretson, M. Myskow, G. Dixon.
Expression of the BCL-2 protein in normal and dysplastic bronchial ephitelium and in lung carcinomas.
Br J Cancer, 72 (1995), pp. 164-169
[42.]
M. Ñau, B. Brooks, J. Battey, E. Sausville, A.F. Gazdar, A.R. Kirsch, et al.
L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.
Nature, 318 (1985), pp. 69-73
[43.]
A. Wong, J. Rupper, J. Eggleston, S.R. Hamilton, S.B. Baylin, B. Vogelstein.
Gene amplification of C-myc in small cell carcinoma of the lung.
Science, 233 (1986), pp. 461-465
[44.]
A.G. Knudson.
Hereditary cáncer, oncogenes and antioncogenes.
Cáncer Res, 45 (1985), pp. 1.437-1.443
[45.]
T. Strachan, A.P. Read.
PCR-based DNA cloning and DNA analyses.
Human molecular genetics, pp. 129-145
[46.]
S. Lam, C. MacAulay, J. Hung, J. Leriche, A.E. Profio, B. Palcic.
Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscope device.
J Thorac Cardiovasc Surg, 105 (1993), pp. 1.035-1.040
[47.]
I.I. Wistuba, S. Lam, C. Behrens, A.K. Virmani, K.M. Fong, J. Lerich, et al.
Molecular damage in the bronchial epithelium of current former smokers.
J Nati Cancer Inst, 89 (1997), pp. 1.366-1.373
[48.]
L. Mao, J.S. Lee, J.M. Kurie, Y.H. Fan, S.M. Lippman, J.J. Lee, et al.
Clonal genetic alterations in the lungs of current and formers smokers.
J Nati Cancer Inst, 89 (1997), pp. 857-862
[49.]
G.T.Y. Chung, V. Sundaresan, P. Hasleton, R. Rudd, R. Taylor, P.H. Rabbitts, et al.
Clonal evaluation of lung tumors.
Cancer Res, 56 (1996), pp. 1.609-1.614
[50.]
J. Hung, Y. Kishimoto, K. Sugio, A. Virmani, D.D. Mclntire, J.D. Minna, et al.
Alíele specific chromosome 3p deletions occur an early stage in lung cancer.
JAMA, 273 (1995), pp. 558-563
[51.]
P.H. Rabbitts.
Genetic hanges in the development of lung cancer.
Br Med Bull, 50 (1994), pp. 688-697
[52.]
T. Takahashi, H. Takahashi, H. Suzuki, T. Hida, Y. Sekido, Y. Ariyoshi, et al.
The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern.
Oncogene, 6 (1991), pp. 1.775-1.778
[53.]
I. Chica, T. Takashahi, M.M. Nau, D. D’Amico, D.T. Curiel, T. Mitsudomi, et al.
Mutations in the p53 gene are frequent in primary resected non-small cell lung cancer.
Oncogene, 5 (1990), pp. 1.603-1.610
[54.]
D. Sidransky.
Importance of chromosome 9p loss in human lunc cancer.
J Nati Cáncer Inst, 87 (1995), pp. 1.201-1.202
[55.]
Y. Kishimoto, K. Sugio, J. Hung, A.K. Virmani, D.D. Mclntire, J.D. Minna, et al.
Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers.
J Nati Cáncer Inst, 87 (1995), pp. 1.224-1.229
[56.]
J. Yokota, T. Akiyama, Y. Fung, W.F. Benedict, Y. Namba, M. Hanaoka, et al.
Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung.
Oncogene, 3 (1988), pp. 471-475
[57.]
R. Dolí, R. Peto.
Mortality in relation to smoking: 20 years observation in male British doctors.
Br Med J, 2 (1976), pp. 1.525-1.536
[58.]
M.T. Halpern, B.W. Gillespie, K.E. Warner.
Patterns of absolute risk of lung cancer mortality in former smokers.
J Nati Cancer Inst, 85 (1993), pp. 457-464
[60.]
J.L. Mulshine, F. Scott.
Molecular markers in early cancer detection.
New screening tools. Chest, 107 (1995), pp. 280-286
[61.]
D.M.D. Evans, G. Shelley.
Respiratory cytodiagnosis: study in observer variation and its relation to quality of material.
Thorax, 37 (1982), pp. 259-263
[62.]
L. Tao.
Cytologic diagnosis of radiographically occult squamous cell carcinoma of the lung.
Cancer, 50 (1982), pp. 1.580-1.586
[63.]
L.B. Woolner, R.S. Fontana, D.A. Cortese, D.R. Sanderson, P.E. Bernatz, W.S. Payne, et al.
Roentgenographically occult lung cancer: pathologic findings and frequency of multicentricity during a 10 year period.
Mayo Clin Proc, 59 (1984), pp. 453-466
[64.]
R.S. Fontana, D.R. Sanderson, W.F. Taylor, L.B. Woolner, W.E. Miller, J.R. Muhm, et al.
Early lung cancer detection: summary and conclusions.
Am Rev Respir Dis, 130 (1984), pp. 565-570
[65.]
L.E. Koss.
Diagnostic cytology and its histopathologic bases.
JB Lippincott, (1979),
[66.]
A. Bocking, S. Biesterfeld, R. Chatelain, G. Gien-Gerlach, E. Esser.
Diagnsosi of bronchial carcinoma on sections of paraffin-embedded sputum. Sensitivity and specificity of an alternative to routine cytology.
Acta Cytol, 36 (1992), pp. 37-47
[67.]
M.S. Tockmam, P.K. Gupta, J.D. Myers.
Sensitive and specific monoclonal antibody recognition of human lung cancer antigen detection.
J Clin Oncol, 6 (1988), pp. 1.685-1.693
[68.]
R.E. Neft, M.M. Murphy, L.A. Tierney, S.A. Belinsky, M. Anderson, G. Saccomanno, et al.
Concurrent fluorescence in sity hybridation and immunocytochemistry for the detection of chromosome aberations in exfoliated bronchial epithelial cells.
Acta Cytol, 41 (1997), pp. 1.769-1.773
[69.]
R. Lubin, G. Zalcman, L. Bouchet, J. Trédaniel, Y. Legros, D. Cazals, et al.
Serum p53 antibodies as early markers of lung cancers.
Nat Med, 1 (1995), pp. 701-702
[70.]
L. Mao, R.H. Hruban, J.O. Boyle, M. Tockman, D. Sidransky.
Detection of oncogene mutations in sputum precedes diagnosis of lung cáncer.
Cáncer Res, 54 (1994), pp. 1.634-1.637
[71.]
P.W. Brandt-Rauf, J.C. Luo, W.P. Carne, S. Smith, I. De Vivo, K. Milling Hemminki, et al.
Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans.
Int J Cancer, 56 (1994), pp. 383-386
[72.]
B. Schlichtholz, J. Trédaniel, R. Lubin, G. Zalcman, A. Hirsch, T. Soussi.
Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in p53 protein.
Br J Cancer, 69 (1994), pp. 808-816
[73.]
J.E. Boers, G.P.M. Ten Velde, B.J.M. Thunnissen.
P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma.
Am J Respir Crit Care Med, 153 (1996), pp. 411-416
[74.]
T. Schenk, J. Ackermann, C. Brunner, P. Schenk, N. Zojer, S. Roka, et al.
Detection of chromosomal aneuploidy by interphase fluorescence in situ hybridization in bronchoscopally gained cells from lung cancer patients.
Chest, 111 (1997), pp. 1.691-1.696
[75.]
K.H. Heyne, S.M. Lippman, J.J. Lee, J.S. Lee, W.K. Hong.
The incidence of second primary tumors in long-term survivors of smallcell lung cancer.
J Clin Oncol, 10 (1992), pp. 1.519-1.524
[76.]
U. Sagman, M. Lisner, E. Maki, F.A. Shepherd, R. Haddad, W.K. Evans, et al.
Second primary malignancies following diagnosis of small cell lung cancer.
J Clin Oncol, 10 (1992), pp. 1.525-1.533
[77.]
M. Melamed, B. Flehinger, D. Miller, R. Osborne, M. Zaman, C. McGinnis, et al.
Preliminary report of the lung cancer detection program in New York.
Cancer, 39 (1977), pp. 369-382
[78.]
M.R. Melamed, B.J. Flhinger, M.B. Zaman, R.T. Heelan, W.A. Perchik, N. Martini.
Screening for early lung cancer: results of the Memorial Sloan-Kettering study in New York.
Chest, 86 (1984), pp. 44-53
[79.]
N.I. Berlin, R. Buncher, R.S. Fontana, J.K. Frost, M.R. Melamed.
The National Cancer Institute cooperative early and detection program: results of the initial screen (prevalence).
Am Rev Respir Dis, 130 (1984), pp. 545-549
[80.]
J.K. Frost, W.C. Ball Jr., M. Levin, M.S. Tockman, R.R. Baker, D. Carter, et al.
Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study.
Am Rev Respir Dis, 130 (1984), pp. 549-554
[81.]
K. Ebeling, P. Nischam.
Screening for the lung cancer: results from a case-control study.
Int J Cancer, 40 (1987), pp. 141-144
[82.]
R.S. Fontana, D.R. Sanderson, L.B. Woolner, W.F. Taylor, W.E. Miller, J.R. Muhm, et al.
Screening for lung cancer: a critique of the Mayo lung project.
Cancer, 67 (1991), pp. 1.155-1.164
[83.]
T. Sobue, Suzuki, T. Naruke, The Japanese Lung-Cancer-Screening Research Group.
A casecontrol study for evaluating lungcancer screening in Japan.
Int J Cancer, 50 (1992), pp. 230-237
[84.]
D. Eddy.
ACS report on the cancer-related. Health check-up.
CA Cancer J Clin, 30 (1980), pp. 193-240
[85.]
American Cancer Society.
1989 survey of physician's attitudes and practices in early cancer detection.
CA Cancer J Clin, 40 (1990), pp. 77-101
[86.]
D.M. Libby, C.I. Henschke, D.F. Yankelevitz.
The solitary pulmonary nodule: update 1995.
Am J Med, 99 (1995), pp. 491-496
[87.]
C.R. Smart.
Annual Screening Using Chest X-ray Examination for the Diagnosis of Lung Cancer.
Cancer, 72 (1993), pp. 2.295-2.298
[88.]
R.S. Fontana.
Screening for lung cancer.
Screening for cancer, pp. 377-395
[89.]
K.C. Chu.
Technical report on the early cancer trial, early detection branch, division of cancer prevention and control.
National cancer Institute, National Institute of Health, (1991),
[90.]
B.J. Flehinger, M. Kimmel, M.R. Melamed.
Natural history of adenocarcinoma-large cell carcinoma of the lung: conclusions from screening programs in New York and Baltimore.
J Nati Cancer Inst, 80 (1988), pp. 337-344
[91.]
S. Sone, S. Takashima, F. Li, Z. Yang, T. Honda, Y. Maruyama, et al.
Mass screening for lung cancer with mobile spiral computed tomography cancer.
Lancet, 351 (1998), pp. 1.242-1.245
[92.]
J.P. Díaz Jiménez, J.I. Martínez Bailarín.
Fotoquimioterapia. Utilidad de la hematoporfirina y el láser en el tratamiento fotorradioterápico del cáncer.
Láser en medicina y cirugía, pp. 29-33
[93.]
T. Hirano, M. Ishizuka, K. Suzuki, K. Jghida, S. Suzuki, S. Miyaki, et al.
Photodynamic cancer diagnosis and treatment system consisting of pulse lasers and endoscopy spectro image analyzer.
Lasers Life Sci, 3 (1989), pp. 1-18
[94.]
A.E. Profio, D.R. Doiron.
A feasibility study of the use of fluores-cence bronchoscopy for localization of small lung tumors.
Phys Med Biol, 22 (1977), pp. 949-957
[95.]
H. Kato, D.A. Cortese.
Early detection of lung cancer by means of hematoporphyrin derivative fluorescence and laser photoradiation.
Clin Chest Med, 6 (1985), pp. 237-253
[96.]
P.T. Reid, R.M. Rudd.
Diagnostic investigations in lung cancer.
Eur Respir Monogr, 1 (1995), pp. 188-211
[97.]
P. Vermylen, T. Berghmans, C. Roufosse, P. Pierard, V. Ninane, J.P. Sculier.
Diagnosis and treatment of early-stage bronchial cancer: current status.
Rev Med Brux, 18 (1997), pp. 347-352
[98.]
J.P. Díaz-Jiménez, J. Sans Torres, C. Domingo, Martínez, I. -Ballarín, M.J. Catro, F. Manresa.
Primer caso en España de detección de un carcinoma escamoso oculto mediante la utilización del sistema LIFE.
Med Clin (Barc), 1 (1998), pp. 217-219
[99.]
J. Flung, S. Lam, J.C. Le Riche, O.B. Palci.
Autofluorescence of normal and malignant bronchial tissue.
Lasers Surg Med, 11 (1991), pp. 99-105
[100.]
S. Lam, J. Hung, B. Palcio.
Mechanism of detection of early lung cancer by ratio fluorometry.
Lasers Life Sci, 4 (1991), pp. 67-73
[101.]
S. Lam, C. MacAuley, B. Palcio.
Detection and localization of early lung cancer by imging techniques.
Chest, 103 (1993), pp. 12-14
[102.]
H. Kato, N. Ikeda.
The role of fluorescence diagnosis in the early detection of high-risk bronchial lesions.
J Bronchol, 5 (1998), pp. 273-274
[103.]
B.J. Venmans, H. Van der Linden, T.J. Van Boxem, P.E. Postmus, E.F. Smit, T.G. Sutedja.
Early detection of preinvasive lesions in high-risk patients. A comparison of conventional flexible and fluorescence bronchoscopy.
J Bronchol, 5 (1998), pp. 280-283
[104.]
N. Awadh, C. McAulay, S. Lam.
Detection and treatment of superficial lung cancer by using gamma-aminolevulínico acid: a preliminary report.
J Bronchol, 4 (1997), pp. 13-17
[105.]
F. De Blasio, C. Prisco, A. Pezza.
Utilitá degli anticorpi monoclonali nella diagnosi di carcinoma polmonare.
Arch Monaldi Mal Torace, 45 (1990), pp. 195-202
[106.]
J. Zhou, J.L. Mulshine, E.J. Unsworth, F.M. Scott, I.M. Avis, M.D. Vos, et al.
Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogenous nuclear ribonucleoprotein-A2/B 1 as the antigen for monoclonal antibody 703D4.
J Biol Chern, 271 (1996), pp. 10.760-10.766
[107.]
R.B. Cameron.
Malignancies of the lung.
Practical oncology, pp. 189-204
[108.]
W. Ebert, T.H. Muley, P. Drings.
Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?.
Anticancer Res, 16 (1996), pp. 2.161-2.168
[109.]
R. Partanen, H. Koskinen, K. Hemminki.
Tumor necrosis factoralfa (TNF-alfa) in patients who have asbestosis and develop cancer.
Occup Environ Med, 52 (1995), pp. 316-331
[110.]
J. Niklinsky, M. Furntan, M. Rapellino, L. Chyczewski, J. Laudanski, J. Oliaro, et al.
CYFRA 21.1 determination in patients with non-small cell lung cancer: clinical utility for the detection of recurrences.
J Cardiovasc Surg, 36 (1995), pp. 501-504
[111.]
E.N. Milld, C.L. Fishman, J. Scholes, S.E. Anderson, W.N. Rom, D.R. Jacobson.
Detection of K-ras oncogene mutations in broncholaveolar lavage fluid for lung cancer diagnosis.
J Natl Cancer Inst, 87 (1995), pp. 1.056-1.060
[112.]
M.J. Chillón.
Valor de la mieloperoxidasa en el lavado broncoalveolar de cáncer de pulmón [tesis doctorall.
UCM, (1999),
Copyright © 1999. Sociedad Española de Neumología y Cirugía Torácica
